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AbstrACt
background Recent research has shown that in 
schistosome-endemic areas preschool-aged children (PSAC), 
that is, ≤5 years, are at risk of infection. However, there exists 
a knowledge gap on the dynamics of infection and morbidity 
in this age group. In this study, we determined the incidence 
and dynamics of the first urogenital schistosome infections, 
morbidity and treatment in PSAC.
Methods Children (6 months to 5 years) were recruited 
and followed up for 12 months. Baseline demographics, 
anthropometric and parasitology data were collected 
from 1502 children. Urinary morbidity was assessed by 
haematuria and growth-related morbidity was assessed 
using standard WHO anthropometric indices. Children 
negative for Schistosoma haematobium infection were 
followed up quarterly to determine infection and morbidity 
incidence.
results At baseline, the prevalence of S haematobium 
infection and microhaematuria was 8.5% and 8.6%, 
respectively. Based on different anthropometric indices, 
2.2%–8.2% of children were malnourished, 10.1% 
underweight and 18.0% stunted. The fraction of morbidity 
attributable to schistosome infection was 92% for 
microhaematuria, 38% for stunting and malnutrition at 
9%–34%, depending on indices used. S haematobium-
positive children were at greater odds of presenting 
with microhaematuria (adjusted OR (AOR)=25.6; 95% 
CI 14.5 to 45.1) and stunting (AOR=1.7; 95% CI 1.1 to 
2.7). Annual incidence of S haematobium infection and 
microhaematuria was 17.4% and 20.4%, respectively. 
Microhaematuria occurred within 3 months of first 
infection and resolved in a significant number of children, 
12 weeks post-praziquantel treatment, from 42.3% to 
10.3%; P<0.001.
Conclusion We demonstrated for the first time the incidence 
of schistosome infection in PSAC, along with microhaematuria, 
which appears within 3 months of first infection and resolves 
after praziquantel treatment. A proportion of stunting and 
malnutrition is attributable to S haematobium infection. The 
study adds scientific evidence to the calls for inclusion of 
PSAC in schistosome control programmes.
Key questions
What is already known about this topic?
 ► Epidemiological studies indicate that preschool-
aged children (PSAC) aged ≤5 years are exposed to 
schistosome infection, the consequences of which 
manifest later in life.
 ► Unlike school-aged children, there are no 
longitudinal studies tracking the dynamics of 
new infections, the development of morbidity and 
implications on current and future health in this age 
group.
What are the new findings?
 ► We determined for the first time levels of 
schistosome morbidity in PSAC attributable to 
Schistosoma haematobium infection, that is, 92% 
of microhaematuria, 38% of stunting and depending 
on what index is used, 9%–34% of malnutrition. 
We recorded significant annual incidence of 
new schistosome infection (17.7%) and urinary 
morbidity (microhaematuria; 20.4%) with significant 
quarterly incidences.
 ► We showed that microhaematuria occurred within 
3 months of first infection and resolved after 
praziquantel (PZQ) treatment.
 ► We indicated that a significant amount of morbidity, 
as measured by microhaematuria, resolved 
within 3 months of effective treatment with PZQ 
(significant reduction from 42.3% vs to 10.3% 
(P<0.0001)).
recommendations for policy
 ► The findings indicate that schistosome  
morbidity in PSAC can be reversed by PZQ  
treatment.
 ► The findings contribute to the scientific evidence 
base for prioritising schistosome treatment in PSAC, 
to reduce infection and morbidity and promote child 
health and development.
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IntroduCtIon
Of the 123 million children worldwide affected with 
schistosomiasis, about 50 million are preschool-aged chil-
dren (PSAC), that is, ≤5 years.1 Nonetheless, schistosome 
infection and morbidity dynamics in this age group are 
less characterised compared with school-aged children 
(SAC), that is, ≥6 years. For example, there are several 
studies describing and quantifying schistosome-related 
morbidity including haematuria, nutritional deficien-
cies and delayed growth and cognition in SAC2 3 but no 
comparable comprehensive studies in PSAC.
Epidemiological studies in PSAC clearly indicate that 
infection occurs in early childhood,4–7 and if untreated, 
the infection can lead to health consequences later in life.8 
Despite this importance of childhood infections, there is 
a paucity of longitudinal studies tracking the dynamics 
of new first infections, the development of morbidity 
and implications on current and future health in this 
age group. The definition of schistosome pathology and 
morbidity continues to be refined in attempts to better 
characterise clinical manifestations, for example, as with 
female genital schistosomiasis,9 and to identify appli-
cable morbidity markers of disease, for example, urine 
albumin–creatinine ratio.10 Growth and nutrition-related 
morbidities associated with schistosomiasis have also 
only recently become more widely recognised.11 There is 
therefore a need to collate all of this new knowledge to 
better define schistosomiasis in PSAC, where manifesta-
tions of disease are poorly described.6
In this study, we aimed to describe the baseline dynamics 
of schistosome infection and morbidity in Zimbabwean 
PSAC exposed to Schistosoma haematobium. A cohort of 
schistosome-negative children was followed for a year 
to document infection and morbidity incidence, as well 
as the effects of treatment on infection and morbidity. 
This study investigates the ability of existing diagnostic 
and morbidity tools to quantify and monitor early infec-
tion and morbidity. It also contributes to disease burden 
estimates and the dynamics of infection and morbidity in 
PSAC. This knowledge will inform the design and imple-
mentation of interventions targeted at this age group.
MetHods
Consent
Permission to conduct the study in the province was 
obtained from the Provincial Medical Director. Prior to 
enrolment, the study aims and procedures were explained 
to all participants and their parents/guardians in English 
or in the local language, Shona. Written informed consent 
was obtained from the participants’ parents/guardians as 
appropriate. Recruitment into the study was voluntary and 
parents/guardians were free to withdraw the participants at 
any time with no further obligation.
study site and period
The study was conducted in 13 villages in the Shamva 
district, northeast of Zimbabwe (17°10′0″S 31°40′0″E) 
from February 2016 through to February 2017. This is 
one of seven districts in the Mashonaland Central prov-
ince of Zimbabwe, whose people are primarily subsistence 
farmers. There is a cold dry (April–July), hot dry (August–
October) and rainy season (November–March).12 13 The 
area was selected for this study on urogenital schistoso-
miasis because the prevalence of S haematobium is high 
(>50%), while the prevalence of Schistosoma mansoni and 
soil-transmitted helminths is low (<15%).14
study design
This study was part of a larger longitudinal parasitological 
and immunological project, following the treatment-re-
infection study design widely used in human helminth 
field studies. There was a cross-sectional study at base-
line, followed by a 1-year longitudinal study. Recruited 
children were screened at baseline for schistosome infec-
tion and morbidity to describe the epidemiology of infec-
tion and morbidity in this population. The larger study 
is comparing the impact of regular quarterly screening 
and treatment (group 1) and biennial screening and 
treatment (group 2). This study reports on the findings 
in the children screened quarterly (group 1). Following 
the baseline recruitment, age and sex-matched S haemato-
bium-negative children who fulfilled the inclusion criteria 
were randomly allocated into groups 1 and 2. A total of 
1783 children were invited to participate, of which 1502 
provided samples for parasitological diagnosis at base-
line. After allocation to the two groups of the study, 525 
children who were schistosome-negative by egg count, 
provided a blood sample for serological assays and 
consented to participate in the longitudinal follow-up, 
formed the group 1 cohort, which was followed up every 
3 months to detect new schistosome infections by egg 
count, and morbidity by microhaematuria.
Children were recruited from crèches, early child 
development centres, and preschools. Parents/guard-
ians of children not attending any of the educational 
programmes (eg, children <3 years) were invited through 
the community nurse and village health workers to report 
to the sampling centre; that is, the centre used by the 
community for the Expanded Program for Immunisa-
tion (eg, school or primary health centre) for enrolment 
into the project. A questionnaire designed in English and 
translated into the local dialect (Shona) was adminis-
tered to gather demographic data and establish exposure 
behaviour.
study inclusion criteria
At baseline, the study enrolled children aged 6 months 
to 5 years who met the following inclusion criteria. Partic-
ipants had to (i) be lifelong residents of the study area, 
(ii) have no previous antihelminthic treatment, (iii) be 
negative for S mansoni and (iv) consent to participate. 
To be included in the longitudinal cohort, children who 
had fulfilled the inclusion criteria described above had to 
meet an additional criterion of being diagnosed negative 
for S haematobium by egg count at baseline.
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Anthropometry
Weight (nearest 0.1 kg) and height (nearest 0.1 cm) 
without shoes and in light clothing was measured using 
an electronic scale and a stadiometer, respectively. For 
very young babies, height was measured with an infan-
tometer baby board, and weight measured with a baby 
scale. The mid-upper arm circumference (MUAC) was 
measured (nearest 1 mm) using a child MUAC tape; on 
the left arm, midpoint between the shoulder and the tip 
of the elbow, with the arm relaxed and hanging down the 
body. Growth and nutritional status was assessed using 
the WHO Anthro software V.3.0.1 (http://www. who. int/ 
childgrowth/ en/).15 This generated Z-scores for specific 
measures of nutrition and growth, that is, stunting by 
height-for-age (HAZ), underweight by weight-for-age 
(WAZ) and body mass index-for-age (BAZ) and malnu-
trition by MUAC (MUAC and MUACZ) and weight-for-
height (WHZ). Measures were considered abnormal 
when Z scores were <–2.16
Parasitological diagnosis
About 50 mL of urine sample was collected from each 
participant on three successive days and a stool spec-
imen was collected on a single day from each partici-
pant. Samples were collected between 10:00 hours and 
14:00 hours, and processed within 2 hours of collection. 
For very young children, urine bags (Hollister 7511 
U-Bag Urine Specimen Collector, Hollister, Chicago, Illi-
nois, USA) and disposable diapers were used to collect 
urine and stool samples respectively. Urine samples were 
examined microscopically for S haematobium infection 
following the standard urine filtration method17 and the 
number of eggs was reported per 10 mL of urine. Stool 
samples collected were processed using the Kato–Katz 
method18 and parasite eggs enumerated under a light 
microscope for S mansoni (in duplicates) per gramme of 
stool.
Children were diagnosed positive for helminth infec-
tion if at least one parasite egg was detected in their 
urine or stool samples. All children who were positive for 
S haematobium infection were treated with a single dose 
of praziquantel (PZQ) at the standard 40 mg/kg body-
weight at each visit. Tablets were crushed and adminis-
tered with squash and sliced bread19 by local nurses. A 
post-treatment efficacy check (egg count) was carried 
out for all such participants at each subsequent follow-up 
(12 weeks post treatment).
detection of urinary morbidity
Urine samples collected were examined for visible 
haematuria (macrohaematuria). Microhaematuria 
was determined by dipping the reagent end of Uristix 
reagent strips (Uripath, Plasmatec, UK) into fresh, well-
mixed urine for 40 s and the test area compared with a 
standard colour chart as per manufacturer’s instructions. 
The strength of the colour change indicates varying 
concentrations of blood present in the sample, that is, 
negative, trace, positive (+), positive (++), positive (+++) 
and positive (++++). For analysis purposes, microhaema-
turia was classified as either negative or positive.
sample size calculations
The sample size used for this study was based on the 
larger, longer-lasting study comparing reinfection rates 
following different treatment regimens, of which this 
is a subset. Calculations were based on previous studies 
showing that PZQ treatment reduces reinfection rates by 
at least 50%.5 14 Statistical power analysis was performed 
using Gpower V.3.1.5.20 Based on an expected preva-
lence of 6.7%, as derived from our previous study in 
children aged 1–5 years,21 a sample size of 214 in each 
group would provide α=0.05 and power=0.80. Allowing 
for a 20% dropout rate, the sample size required for each 
group during follow-up was 256. The sample size for the 
larger reinfection study, that is, 525 in a group, was there-
fore sufficient for this aspect of the study.
statistical methods
Data analyses were performed using SPSS V.22 (IBM) 
and GraphPad Prism V.7.02 (GraphPad Software). The 
χ2 (or Fisher’s exact test for small sample sizes) and the 
Mann-Whitney was used to test for differences in cate-
gorical and numerical variables, respectively. Infection 
intensity for S haematobium was defined as the arithmetic 
mean egg count/10 mL of at least two urine samples 
collected on three consecutive days. The egg count data 
was further log-transformed (log10 [egg count+1]) to 
meet the normality assumption of parametric statistics. 
At baseline, infection intensity (log-transformed) and its 
relationship as a function of age was determined using 
a linear regression model. To determine the infection 
prevalence based on a binary response as a function of 
age, logistic regression modelling was used as previously 
described.22 The effect of different factors on the preva-
lence of schistosome infection and morbidity was deter-
mined using logistic regression and the results reported 
as adjusted ORs (AORs) and 95% CI, along with the test 
for significance.
For a given morbidity marker, the attributable fraction 
(AF) in the exposed population (S haematobium-positive) 
and in the total population was calculated using Miettin-
en’s formulae23:
 AF in the exposed population
(
AFe
)
=
(
RR−1)
RR  
 
AF in the total population
(
AFp
)
= Pe× AFe = Pe×
(
RR−1)
RR
 
In the formulae, RR is the risk ratio of morbidity asso-
ciated with exposure, Pe is the prevalence of morbidity 
among the exposed (S haematobium-positive). Because the 
AFs in this case are from a helminth study and estimated 
at the cross-sectional level, we substituted the RR with 
prevalence ratios (PR) as recommended in helminth 
epidemiology.24 The PR was estimated as a ratio of the 
proportion of infected individuals with morbidity to the 
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proportion of uninfected individuals with morbidity. 
AFs were calculated on morbidity markers with PR>1, 
suggesting an increased risk of morbidity from schis-
tosome infection.24 Treatment efficacy was assessed by 
means of egg reduction rates (ERR) and cure rates (CR) 
as described previously.21
Approximate CIs were calculated using the modified 
Wald method25 and P<0.05 was considered significant.
results
demographics
Of the 1502 recruited into the study, 794 (52.9%) were 
male. Age range was between 0.5 and 5 years (median=3.5 
years; IQR 2.5–4.3). The youngest participant in whom 
S haematobium infection was detected was a year old. 
Maximum loss to follow-up was recorded at first follow-up 
in May 2016 (64 participants; 12.2%). Overall follow-up 
rates in the longitudinal cohort, including participants 
for post-treatment efficacy check, were 87.8% in May 
2016, 93.7% in August 2016, 95.1% in November 2016 
and 88.8% in February 2017.
S haematobium epidemiology at baseline
S haematobium infection prevalence at baseline in the 1502 
participants was 8.5% (95% CI 7.2 to 10.0). The median 
age of children positive for infection was significantly 
higher compared with those negative for infection (4.0 
vs 3.5 years; P=0.001). Infection prevalence increased 
with age as shown in figure 1A,B. The overall mean infec-
tion intensity was 7.9 eggs/10 mL urine (95% CI 6.4 to 
9.7). The majority of children, 93.7% (95% CI 87.9 to 
97.0) presented with light infections (<50 eggs/10 mL 
of urine) based on the WHO classification.19 Infection 
intensity increased with age as shown in figure 1C,D. 
There was no significant difference in infection preva-
lence between males and females; 8.9% (95% CI 7.1 to 
11.1) and 8.1% (95% CI 6.3 to 10.4; P=0.067), respec-
tively.
Morbidity at baseline
Prevalence of urinary morbidity was 0.7% (95% CI 0.3 
to 1.5) for macrohaematuria and 8.6% (95% CI 6.9 to 
10.6) for microhaematuria. Malnutrition measured by 
different indices were as follows: MUAC, 2.2% (95% 
CI 1.4 to 3.2), MUACZ, 7.4% (95% CI 6.0 to 9.1) and 
WHZ, 8.2% (95% CI 6.8 to 9.9). Prevalence of under-
weight measured by WAZ was 10.1% (95% CI 8.5 to 
11.9), and stunting by HAZ was 18.0% (95% CI 16.0 to 
20.3). Comparing infected versus uninfected children, 
prevalence of microhaematuria (43.5%; 95% CI 34.8 to 
52.6 vs 3.4%; 95% CI 2.4 to 5.0; P<0.001) and stunting 
(27.0%; 95% CI 19.9 to 35.6 vs 17.0%; 95% CI 14.9 to 
Figure 1 (A) Schistosoma haematobium infection prevalence with age; prevalence varied with age (P<0.001) and (B) age-
predicted probability of infection; prevalence increased as children grew older (P=0.002). (C) S haematobium infection intensity 
with age; intensity varied with age (P<0.001) and (D) age-predicted intensity of infection; infection intensity increased as 
children grew older. Error bars indicate 95% CI (A) or SEM (C), and shaded areas indicate 95% CI; (B, D).
group.bmj.com on April 12, 2018 - Published by http://gh.bmj.com/Downloaded from 
Osakunor DNM, et al. BMJ Glob Health 2018;3:e000661. doi:10.1136/bmjgh-2017-000661 5
BMJ Global Health
19.4; P=0.009) was significantly higher among children 
with S haematobium infection.
Morbidity attributable to S haematobium infection
Morbidities from schistosome infection are not specific 
and may relate to different physiological, biochemical 
and immunological processes. We determined how much 
of the detected morbidity was attributable to schistosome 
infection by first determining PRs. All the morbidity 
markers considered had PR >1 (significant association 
with schistosome infection) except underweight by BAZ 
(table 1). Based on AFs, microhaematuria was the most 
dominant morbidity marker attributed to schistosome 
infection both in infected children and at the population 
level. Macrohaematuria, on the other hand, was highly 
attributable to schistosome infection in the infected 
population but this was not the case in the total popu-
lation. Of the anthropometric markers, stunting was the 
most dominant marker attributed to schistosome infec-
tion both at the population level and among the infected 
children (figure 2).
likelihood of schistosome infection and morbidity
Multiple logistic regression analysis showed that with 
every unit increase in age, children were more likely to 
acquire S haematobium infection (AOR=1.4; 95% CI 1.1 
to 1.8; P=0.005). Children who presented with microhae-
maturia were more likely to be positive for S haematobium 
infection (AOR=21.8; 95% CI 11.7 to 40.7; P<0.001) as 
shown in figure 3A. Similarly, children presenting with 
S haematobium infection were more likely to present with 
microhaematuria (AOR=25.6; 95% CI 14.5 to 45.1; 
P<0.001) and stunting (AOR=1.7; 95% CI 1.1 to 2.7; 
P=0.014) as shown in figure 3B.
Incidence of infection and morbidity
To determine infection and morbidity incidence, 525 
schistosome-negative children were followed quarterly 
for 12 months to determine schistosome infection and 
morbidity acquired in the previous three months. Based 
on the longitudinal data, annual incidence of S haemato-
bium infection was 17.4% (95% CI 13.7 to 21.8) and that 
of microhaematuria was 20.4% (95% CI 15.8 to 26.0). S 
haematobium incidence rates in the dry season was 4.9% 
in May (95% CI 3.1 to 7.8) and 6.5% in August (95% 
CI 4.1 to 9.9) while that in the rainy season was 3.8% in 
November (95% CI 2.1 to 6.6) and 3.7% in February 
(95% CI 2.1 to 6.5). Difference in overall incidence rates 
however was not significant between the dry (10.4%; 95% 
CI 7.6 to 14.1) and rainy seasons (7.4% total; 95% CI 5.0 
to 10.9; P=0.175). The quarterly incidence of microhae-
maturia recorded was 2.0% in May (95% CI 0.4 to 5.9), 
2.8% in August (95% CI 1.0 to 6.6), 13.3% in November 
(95% CI 9.6 to 18.3) and 4.3% in February (95% CI 2.2 
to 8.1).
treatment efficacy and effects on morbidity
The treatment efficacy was calculated from children 
positive for infection at baseline and those that became 
infected throughout the year. Thus, a total of 187 chil-
dren were treated for infection (127 at baseline and 60 
from the longitudinal cohort), of which post-treatment 
data were available for 156 (follow-up rate: 83.4%). PZQ 
was efficacious in reducing S haematobium infection, as 
indicated by the high CR (96.2%; 95% CI 91.7 to 98.4) 
and ERR (99.8%; 95% CI 99.2 to 100). In addition, the 
mean infection intensity pretreatment (7.1 eggs/10 mL 
urine; 95% CI 5.9 to 8.6) was significantly reduced at 
post-treatment follow-up (1.1 eggs/10 mL urine; 95% CI 
1.0 to 1.2; P<0.001).
Table 1 Prevalence ratios (PRs) for detected schistosome-
related morbidity
Morbidity Diagnostic tool PR (95% CI)
Microhaematuria Urine dipsticks 12.6 (11.6 to 14.1)
Macrohaematuria Visual inspection 
(colorimetry)
3.4 (1.9 to 5.4)
Stunting HAZ 1.6 (1.05 to 2.31)
Malnutrition WHZ 1.1 (0.9 to 1.4)
MUACZ 1.5 (1.3 to 1.9)
MUAC 1.3 (0.8 to 1.9)
Underweight WAZ 1.4 (1.2 to 1.6)
BAZ 1.0 (0.8 to 1.3)
BAZ, body mass index for age Z scores; HAZ, height-for-age Z 
scores, MUAC, mid-upper arm circumference Z scores; WHZ, 
weight-for-height Z scores; WAZ, weight-for-age Z scores. 
Figure 2 Estimated proportion of morbidity attributable 
to Schistosoma haematobium infection in the infected 
population (blue; AFe) and in the total population (red; AFp). 
Error bars indicate 95% CIs. BAZ, body mass index-for-age 
Z scores; HAZ, height-for-age Z scores; MUAC, mid-upper 
arm circumference Z scores; WAZ, weight-for-age Z scores; 
WHZ, weight-for-height Z scores .
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To determine the effects of treatment on morbidity 
identified at baseline, data for microhaematuria were 
available for 78 of the 127 S haematobium-positive cases 
identified. Within this cohort, 42.3% (95% CI 32.0 
to 53.4) were positive for microhaematuria and this 
declined significantly post-treatment (10.3%; 95% CI 5.1 
to 19.2; P<0.001).
A pooled analysis of participants in whom new infec-
tions were detected throughout the follow-up period 
(group 1) was done to determine the dynamics of 
microhaematuria with infection, before, during and 
post infection. A total of 60 new infections were detected 
throughout the follow-up period. Of this, microhae-
maturia was detected among 18 individuals; 6 (33.3%) 
preinfection, 11 (61.1%) during infection and 2 (11.1%) 
post treatment. In 61.1% of these individuals, microhae-
maturia coincided with the detection of S haematobium 
infection (within 3 months) and had resolved by the next 
survey at 3 months post treatment of infection (figure 4).
dIsCussIon
Contrary to the previously held assumption of low risk 
to schistosome infection in PSAC,26 the frequency of 
schistosome infections among infants and young chil-
dren is being increasingly recognised.27 We conducted 
a longitudinal study in a cohort of Zimbabwean PSAC 
to determine the prevalence, dynamics and incidence 
of first urogenital schistosome infection and morbidity 
and its associated risks and health impacts. We showed 
that PSAC present with schistosome infection (estimated 
by egg count) and associated morbidity (determined by 
microhaematuria, growth and nutritional markers) from 
an early age. We also found that schistosome infection 
and morbidity can be detected early in PSAC using para-
sitology and microhaematuria within 3 months of infec-
tion and is resolved after treatment.
The observed baseline prevalence of S haemato-
bium infection in PSAC (8.5%) is comparable to levels 
recorded in PSAC in Ghana (11.2%),4 Malawi 10.7%28 
and in our recent studies in Zimbabwe, that is, 13.5%10 
and 6.7%.21 PSAC however present with light infec-
tions22 27 29 and parasitological egg counts underestimate 
the prevalence of schistosome infection.4 22 We anticipate 
this prevalence to increase if the more sensitive sero-
logical diagnostic tools are used.22 In agreement with 
previous findings,7 22 30–32 infection prevalence and inten-
sity increased as children grew older.
The majority of morbidity biomarkers associated with 
schistosomiasis are non-specific and relate to various phys-
iological, biochemical and immunological processes.33 
We determined the prevalence of morbidity and how 
much of this was attributable to S haematobium infec-
tion. Microhaematuria was the most dominant marker 
for schistosome-related morbidity, and children with S 
haematobium infection were more likely to present with 
microhaematuria and vice versa. This agrees with our 
previous findings in Zimbabwe10 and that by researchers 
in Nigeria34 on the significance of microhaematuria as a 
point of care field marker of morbidity in PSAC.
In addition to biomarkers, we also investigated the 
prevalence of stunting and malnutrition in the children. 
To the best of our knowledge, this is the first study to 
show the relationship between S haematobium infection 
and chronic growth failure (Stunting by HAZ) in PSAC, 
although studies on polyparasitism35 36 and few schisto-
some-specific studies37 38 have documented this effect in 
older children. In accordance with our findings, stunting 
as detected in older children and adolescents is believed 
to be the result of chronic antiparasite inflammation 
which persists during childhood.39 Causality is difficult 
to establish in this case due to the lag time between the 
initial infection and the time at which we measured 
growth failure, and the impact of confounding factors 
including diet and coinfections. However, there is the 
need for longer-term studies investigating the impact 
of treatment on growth and development measures in 
PSAC. Statistical modelling suggests that with early, repet-
itive treatment of infection before 6 years of age ‘catch-up 
growth’ can be effectively facilitated.40
While baseline prevalence and intensity of schistosome 
infection have been described in PSAC from several 
African countries, there has not been an incidence study 
published to date. Here, we document the incidence 
of urogenital schistosome infection and morbidity in 
PSAC. Our quarterly incidence is an indication of new 
schistosome infections in PSAC in endemic areas and the 
applicability of current tools (urine filtration and urine 
dipstick) to screen for early infection and morbidity. 
The incidence of microhaematuria and the AF analyses 
suggest that even in the very first episodes of infection 
Figure 3 Forest plot showing (A) the odds of presenting 
with Schistosoma  haematobium infection and (B) odds of 
presenting with microhaematuria (left) and stunting (right). 
Error bars indicate the 95% CIs. *P<0.05, ***P<0.001. Non-
significant variables were excluded from the final logistic 
regression model.
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PSAC suffer morbidity, reflected as microhaematuria; an 
indication of active bladder and ureteral lesions41 42 and 
blood loss even in mild schistosome infection.43
PZQ, the antihelminthic of choice for treatment of 
schistosomiasis, is safe and efficacious in PSAC.44 Our 
results 12 weeks post treatment showed that a single stan-
dard dose of PZQ was effective against S haematobium infec-
tion. This is consistent with reports on the efficacy of PZQ 
treatment for schistosomiasis in PSAC.5 Microhaematuria 
correlates with S haematobium infection,42 45 and treatment 
with PZQ reduces morbidity (microhaematuria) as used 
in large-scale chemotherapy for SAC.33 46 We observed 
that microhaematuria occurred rapidly within 3 months 
of exposure to infection and resolved within 3 months 
after treatment with PZQ. This is an important indicator 
for non-delayed schistosome screening and treatment 
in PSAC, to avert cumulative morbidity which can affect 
overall health.1 Observation from our field studies prove 
that suggestions to empower health workers to screen for 
infection, and making PZQ available in health centres 
for treatment on detection will be an important control 
strategy in this age group.47
The seasonal pattern of infection incidence detected 
is in agreement with the fact that during the dry seasons 
snail vectors and larval schistosomes become concen-
trated at permanent and slow-moving water sources, 
increasing the risk of infection.48 Our observation from 
fieldwork also indicates that during the rainy seasons, 
households are less reliant on water sources for chores 
and children are less likely to visit water bodies for recre-
ational purposes.
The impact of schistosome infection on the health 
of children is likely to be greater than those explored 
here, for example, its impact on neurocognitive devel-
opment. Mechanistic and epidemiological studies sepa-
rating the effects of schistosome infections from other 
confounders would be informative in identifying and 
portioning causation in AFs. The present study did not 
measure the impact of existing feeding, nutrition habits 
and socioeconomic status on stunting and its relationship 
Figure 4 Impact of Schistosoma haematobium infection and praziquantel (PZQ) treatment on morbidity (microhaematuria). 
Microhaematuria status for 18 individual participants is shown at three time points: before, during and post infection 
(post treatment). Each data set (dotted line) represents one individual. Tall, red bars indicate positive microhaematuria, and a 
black dash indicates negative microhaematuria at specific time points.
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to schistosome infections. A limitation of the parasitolog-
ical detection of infection is that some light infections 
may have been missed, resulting in underestimation 
of the infection rates observed. Nonetheless, the study 
allows comparison with other studies while parasitolog-
ical methods remain the predominant schistosome diag-
nostic in PSAC.
ConClusIons
We demonstrated for the first time the incidence of 
schistosome infection and morbidity in PSAC. We have 
also shown that a significant proportion of stunting and 
malnutrition is attributable to S haematobium infection. 
Morbidity assessed by microhaematuria occurs rapidly 
within 3 months of first infection and resolves post treat-
ment. More importantly for childhood health and devel-
opment, schistosome treatment leads to a significant 
decline in microhaematuria and this resolution occurs 
within 3 months of PZQ treatment. The study adds scien-
tific evidence to the calls for inclusion of PSAC in schis-
tosome control programmes. Non-delayed schistosome 
screening and treatment in PSAC is essential to avert 
accumulative morbidity which can affect overall health.
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